SNDX: Key phase II readouts and expanding maintenance therapy drive growth and pipeline momentum
Two commercial drugs are driving strong revenue growth, with recurring post-transplant maintenance therapy emerging as a key driver. Multiple pivotal and phase II readouts are expected in the next year, including for IPF and cGVHD, while new pipeline assets targeting NSCLC and myelofibrosis are adv…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.